Miami Jewish Health

Enrolling Clinical Trials

Marc E Agronin, MD, ***Principal Investigator***

Name of Study: ***Alkahest*** GRF6019

Description of Study: This is a Phase I study, evaluating the safety, tolerability and efficacy of two dosing regimens of GRF6019 plasma via intravenous (IV) infusion.
Indication: Mild to Moderate Alzheimer's Disease

Recruiting Participant Age: 60 - 90

Duration of Study: approximately 7 months (It requires a 5 day inpatient stay and then repeated 12 weeks after).

Name of Study: ***AVANIR*** 15-AVP-786-301/303

Description of Study: The TRIAD Study is a phase III study evaluating an investigational medication to see if it may reduce agitation in patients with dementia related to Alzheimer's disease.
Indication: Dementia of the Alzheimer's type with Agitation

Recruiting Participant Age: 50 - 90 years

Duration of Study: approximately 4 months

Name of Study: ***BOEHRINGER-INGELHEIM*** 1346.23

Description of Study: This is a Phase II study to investigate efficacy and safety of different doses of orally administered BI 425809 compared to placebo in treatment of cognitive impairment due to Alzheimer's Disease.
Indication: Mild to Moderate Alzheimer's Disease

Recruiting Participant Age: 55+

Duration of Study: approximately 7 months (12-week treatment period)

Name of Study: ***EISAI*** E2609-G00-301
Description of Study: This is a phase III study, investigating a drug called Elenbecestat (E2609) in individuals with mild cognitive impairment (MCI) due to Alzheimer's disease or other early stages of mild Alzheimer's disease. The goal of the study is determine whether the drug reduces the amount of protein buildup in the brain of Alzheimer's patients, and if the potential reduction would in turn slow the progression of the disease and its associated memory loss.
Indication: Early Alzheimer's disease
Recruiting Participant Age: 50 – 85 years
Duration of Study: approximately 29 months

Name of Study: ***GENENTECH*** GN39763
Description of Study: This is a phase II study, assessing the efficacy and safety of the investigational antibody MTAU993A for the treatment of Alzheimer's disease, targeting Tau Protein in the brain.
Indication: Prodromal to Mild Alzheimer's disease
Recruiting participant Age: 50 - 80 years
Duration of Study: approximately 24 months

Name of Study: ***INTRACELLULAR*** (201 Agitation Study) ITI-007-201/OLE
Description of Study: This is a phase III clinical trial testing the effectiveness and safety of an investigational medication (ITI-007), on treating symptoms of agitation associated with dementia in patients with probable Alzheimer's Disease.
Indication: Probable Alzheimer's disease with Agitation
Recruiting Participant Age: 55 years +
Duration of Study: approximately 2 months

Name of Study- *MIND Study*- Long-Term Nicotine Treatment of Mild Cognitive Impairment. Academia *Study, Funded by the National Institute on Aging (NIA) and conducted by Vanderbilt University and University of Southern California*
Description of Study: The purpose of the Memory Improvement through Nicotine Dosing (MIND) phase II study, is to determine whether nicotine (in patch form) improves memory and functioning in adults diagnosed with MCI
Indication: Mild Cognitive Impairment or Memory Loss
Recruiting Participant Age: 55years +
Duration of Study: 2 years

Name of Study: ***Longeveron***

Description of Study: This is a Phase I study to evaluate the safety and potential efficacy of Longeveron Allogenic Human Mesenchymal Stem Cell (LMSC) Infusion versus placebo in patients with Alzheimer's Disease.

Indication: Mild Alzheimer's Disease

Recruiting Participant Age: 55 - 80

Duration of Study: 52 weeks after infusion with LMSCs

Name of Study: ***NEURIM*** NEUP11-AD2

Description of Study: This is a phase II study evaluating the safety, tolerability, and efficacy of an investigational drug called Piromelatine in patients with mild Alzheimer 's disease. Piromelatine may have the potential to enhance sleeping quality and patterns, which has been shown to be positively associated with overall cognitive function.

Indication: Mild Dementia due to Alzheimer's disease

Recruiting Participant Age: 60 – 85 years

Duration of Study: approximately 7 months

Name of Study: ***Neurotrope NTRP 101-203***

Description of Study: This is a Phase II study assessing the safety, tolerability and efficacy of Bryostatin in treatment of moderately severe to severe Alzheimer's Disease in subjects not receiving Memantine treatment.

Indication: Moderately Severe to Severe Alzheimer's Disease

Recruiting Participant Age: 55 - 85

Duration of Study: approximately 7 months (12-week treatment period)

Name of Study: ***Eli Lilly (TrailBlazer-ALZ)*** 15T-MC-AACG(b)

Description of Study: This is a Phase II, double blinded study, evaluating the safety, tolerability and efficacy of LY3002813 Alone and in Combination with LY3202626 in Early Symptomatic Alzheimer's Disease

Indication: Early Alzheimer's Disease/Progressive Cognitive changes > 6 months

Recruiting Participant Age: 60 - 85

Duration of Study: approximately 18 months.

UPCOMING CLINICAL TRIALS

Name of Study: ***Eisai 201***

Description of Study: This is a Phase II study evaluating the safety, tolerability and efficacy of E2027 in subjects with Dementia with Lewy Bodies.
Indication: Meets criteria for probable Dementia with Lewy Bodies Alzheimer's Disease

Recruiting Participant Age: 50 - 85

Duration of Study: 22 weeks

If you are interested in participating or learning more about our clinical trials, please call

305-514-8710

EDiaz1@miamijewishhealth.org

RCastaneda@miamijewishhealth.org